Immunogenicity of recombinant human erythropoietin in Korea: A two-year cross-sectional study

Biologicals

Volumn 40, Issue 4, 2012, Pages 254-261

  Shin, Sug Kyun ^a   Moon, Sung Jin ^b   Ha, Sung Kyu ^c   Jo, Young Il ^d   Lee, Tae Won ^e   Lee, Young Sook ^f   Kim, Yang Wook ^g   Kim, Dae Joong ^h   Kim, Jin Kuk ⁱ   Yoo, Tae Hyun ^j   Lee, Kyu Beck ^k   Choi, Seung Ok ^l   Kang, Ea Wha ^a   Lee, Kang Wook ^m   Kim, Sung Jo ⁿ   Kim, Sang Kyum ^o   Heo, Tae Hwe ^p  

^a National Health Insurance Corporation   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Konkuk University Hospital   (South Korea)

^e Kyung Hee University College of Medicine   (South Korea)

^f Eulji University School of Medicine   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ Soonchunhyang University College of Medicine   (South Korea)

^j Yonsei University College of Medicine   (South Korea)

^k School of Medicine   (South Korea)

^l Wonju Severance Christian Hospital   (South Korea)

^m Chungnam National University College of Medicine   (South Korea)

ⁿ Hoseo University   (South Korea)

^o Chungnam National University   (South Korea)

^p The Catholic University of Korea   (South Korea)

more..

Author keywords

Ab; Antibody; End stage renal disease; EPO; Erythropoietin; ESRD; Immunogenicity; NT; PRCA; Pure red cell aplasia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPORON; ERYTHROPOIETIN ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADULT; ANTIBODY TITER; APLASTIC ANEMIA; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNOGENICITY; INFORMED CONSENT; KIDNEY FAILURE; KOREA; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SERODIAGNOSIS;

ADULT; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 84863774587     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.02.003     Document Type: Article

References (22)

1. Navarro J.F. In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 2003, 18:2222-2226.
2. McKoy J.M., Stonecash R.E., Cournoyer D., Rossert J., Nissenson A.R., Raisch D.W., et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008, 48:1754-1762.
3. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004, 351:1403-1408.
4. Locatelli F., Aljama P., Barany P., Canaud B., Carrera F., Eckardt K.U., et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. Nephrol Dial Transplant 2004, 19:288-293.
5. Schonholzer C., Keusch G., Nigg L., Robert D., Wauters J.P. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases. Nephrol Dial Transplant 2004, 19:2121-2125.
6. Kharagjitsingh A.V., Korevaar J.C., Vandenbroucke J.P., Boeschoten E.W., Krediet R.T., Daha M.R., et al. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005, 68:1215-1222.
7. Casadevall N., Cournoyer D., Marsh J., Messner H., Pallister C., Parker-Williams J., et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004, 73:389-396.
8. Shin S.K., Ha S.K., Lee K.W., Yoo T.H., Yun S.R., Yoon S.H., et al. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. J Pharm Biomed Anal 2010, 52:289-293.
9. Cournoyer D., Toffelmire E.B., Wells G.A., Barber D.L., Barrett B.J., Delage R., et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004, 15:2728-2734.
10. El-Din M.M., Attia F.M., Labib S.M., Omar W. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis. Int J Lab Hematol 2010, 32:336-343.
11. Castelli G., Famularo A., Semino C., Machi A.M., Ceci A., Cannella G., et al. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 2000, 41:313-318.
12. Ha S.K., Yang S.J., Shin S.K., Jo Y.I., Baek K.M., Hong S.H., et al. Comparative analysis of screening results from various ELISA formats used for detection of anti-erythropoietin antibodies in Korean patients. Biomolecules Ther 2010, 18:184-190.
13. Thorpe R., Swanson S.J. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005, 20(Suppl. 4):iv16-iv22.
14. Hoesel W., Gross J., Moller R., Kanne B., Wessner A., Muller G., et al. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J Immunol Methods 2004, 294:101-110.
15. Fibi M.R., Aslan M., Hintz-Obertreis P., Pauly J.U., Gerken M., Luben G., et al. Human erythropoietin-specific sites of monoclonal antibody-mediated neutralization. Blood 1993, 81:670-675.
16. 3H-thymidine uptake assay for neutralizing antibodies. J Immunol Methods 2005, 300:179-191.
17. Mandreoli M., Finelli C., Lopez A., Ascani S., Vianelli N., Baccarani M., et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004, 44:757-761.
18. Gross J., Moller R., Bischoff S., Canaan-Kuhl S., Fromme M., Henke W. Detection and characterization of antibodies against recombinant human erythropoietin by RIPA, ELISA and neutralization assay in patients with renal anemia. J Immunol Methods 2008, 336:152-158.
19. Brodsky R.A. Biology and management of acquired severe aplastic anemia. Curr Opin Oncol 1998, 10:95-99.
20. Marsh J.C., Ball S.E., Darbyshire P., Gordon-Smith E.C., Keidan A.J., Martin A., et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003, 123:782-801.
21. Heuser M., Ganser A. Recombinant human erythropoietin in the treatment of nonrenal anemia. Ann Hematol 2006, 85:69-78.
22. van der Putten K., Braam B., Jie K.E., Gaillard C.A. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008, 4:47-57.